Louisiana State Employees Retirement System Has $484,000 Position in Artivion, Inc. (NYSE:AORT)

Louisiana State Employees Retirement System lowered its holdings in Artivion, Inc. (NYSE:AORT) by 8.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,200 shares of the company’s stock after selling 1,700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Artivion were worth $484,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of AORT. nVerses Capital LLC bought a new stake in shares of Artivion during the second quarter worth $28,000. RiverPark Advisors LLC bought a new stake in shares of Artivion during the second quarter worth $55,000. Allspring Global Investments Holdings LLC raised its position in shares of Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after acquiring an additional 4,154 shares during the last quarter. RW Investment Management LLC bought a new stake in shares of Artivion during the second quarter worth $219,000. Finally, Intech Investment Management LLC bought a new stake in shares of Artivion during the second quarter worth $253,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insider Buying and Selling at Artivion

In related news, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the sale, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the sale, the director now directly owns 34,159 shares of the company’s stock, valued at $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,109 shares of company stock valued at $951,935. 8.10% of the stock is currently owned by corporate insiders.

Artivion Price Performance

Shares of NYSE AORT opened at $27.91 on Wednesday. The firm has a market cap of $1.17 billion, a P/E ratio of -132.90 and a beta of 1.75. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. Artivion, Inc. has a 1-year low of $13.18 and a 1-year high of $29.24. The business’s 50 day moving average is $26.06 and its 200-day moving average is $25.00.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The firm had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Equities research analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

AORT has been the subject of a number of recent analyst reports. Oppenheimer upped their price objective on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Stifel Nicolaus upped their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. JMP Securities began coverage on Artivion in a report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Artivion in a research note on Friday, September 27th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion presently has an average rating of “Buy” and a consensus price target of $30.60.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.